Fragile X Syndrome in Adulthood: A Study of Electronic Health Records.

The Black sample is only 44 adults, which limits the precision of any finding specific to that group. The study measures frequency of medical encounters (billing codes), not actual disease prevalence. More encounters could reflect more disease, but also more access to care, more referrals, or more documentation. Black FXS patients had medical records twice as long as their Black controls (7.4 vs 3.5 years), and although this was statistically controlled, the authors acknowledge it may still inflate encounter counts. The study is limited to Black and White non-Hispanic adults; patients of other racial and ethnic groups were excluded due to small numbers. The data come from billing and clinical records, not from research-specific assessments, so the range of questions that could be asked is limited. Most patients had at least some contact with the Rush FXS specialty clinic, so the sample may not represent adults without access to dedicated FXS care. Some EHR entries may reflect medication side effects rather than primary diagnoses (e.g., elevated liver enzymes from behavioral medications). A small number of undiagnosed FMR1 premutation carriers may be included in the control group, since genetic testing is not routine in this network. Sex-specific analyses were not possible due to the small number of women.

Do not read the elevated encounter rates in Black adults with Fragile X as proof of greater underlying disease severity. The study counts billing codes, not confirmed diagnoses, and the authors note that Black FXS patients had medical records twice as long as their controls (7.4 vs 3.5 years), which could inflate encounter counts even after statistical adjustment. The Black sample is also only 44 people, so individual condition-level estimates are imprecise.